Rep. Robert Bresnahan, Jr. Buys Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of West Pharmaceutical Services, Inc. (NYSE:WST). In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in West Pharmaceutical Services stock on February 25th. The trade occurred in the Representative’s “JP MORGAN BROKERAGE ACCOUNT” account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Intuit (NASDAQ:INTU) on 3/7/2025.
• Sold $1,001 – $15,000 in shares of Tesla (NASDAQ:TSLA) on 3/6/2025.
• Purchased $1,001 – $15,000 in shares of SEA (NYSE:SE) on 3/5/2025.
• Sold $1,001 – $15,000 in shares of Credo Technology Group (NASDAQ:CRDO) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Meta Platforms (NASDAQ:META) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Twilio (NYSE:TWLO) on 3/4/2025.
• Sold $15,001 – $50,000 in shares of Alibaba Group (NYSE:BABA) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Zoom Video Communications (NASDAQ:ZM) on 3/4/2025.
• Purchased $1,001 – $15,000 in shares of Intel (NASDAQ:INTC) on 3/3/2025.
• Purchased $1,001 – $15,000 in shares of Snowflake (NYSE:SNOW) on 3/3/2025.

West Pharmaceutical Services Price Performance

Shares of NYSE:WST opened at $222.08 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.23 and a current ratio of 2.79. West Pharmaceutical Services, Inc. has a one year low of $197.01 and a one year high of $396.75. The company has a 50-day simple moving average of $263.98 and a 200-day simple moving average of $297.82. The stock has a market capitalization of $16.06 billion, a price-to-earnings ratio of 33.20, a PEG ratio of 6.74 and a beta of 1.09.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, February 13th. The medical instruments supplier reported $1.82 earnings per share for the quarter, topping analysts’ consensus estimates of $1.75 by $0.07. The company had revenue of $748.80 million during the quarter, compared to analysts’ expectations of $739.59 million. West Pharmaceutical Services had a return on equity of 18.60% and a net margin of 17.03%. On average, analysts predict that West Pharmaceutical Services, Inc. will post 6.62 EPS for the current year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 7th. Shareholders of record on Wednesday, April 30th will be paid a $0.21 dividend. The ex-dividend date of this dividend is Wednesday, April 30th. This represents a $0.84 dividend on an annualized basis and a yield of 0.38%. West Pharmaceutical Services’s dividend payout ratio is presently 12.56%.

Wall Street Analysts Forecast Growth

WST has been the subject of a number of analyst reports. Bank of America upped their price objective on shares of West Pharmaceutical Services from $350.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Citigroup started coverage on shares of West Pharmaceutical Services in a research report on Wednesday, January 8th. They issued a “buy” rating and a $400.00 price objective for the company. Evercore ISI began coverage on West Pharmaceutical Services in a report on Tuesday, March 18th. They issued an “outperform” rating and a $275.00 price objective on the stock. Wolfe Research began coverage on West Pharmaceutical Services in a research note on Friday, December 13th. They set a “peer perform” rating for the company. Finally, UBS Group upgraded West Pharmaceutical Services from a “neutral” rating to a “buy” rating and lifted their price target for the company from $350.00 to $390.00 in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $332.50.

Institutional Investors Weigh In On West Pharmaceutical Services

A number of institutional investors and hedge funds have recently modified their holdings of WST. Norges Bank purchased a new stake in West Pharmaceutical Services during the fourth quarter worth $290,604,000. Van ECK Associates Corp raised its stake in shares of West Pharmaceutical Services by 5,074.0% during the 4th quarter. Van ECK Associates Corp now owns 689,493 shares of the medical instruments supplier’s stock worth $225,851,000 after buying an additional 676,167 shares during the last quarter. William Blair Investment Management LLC grew its stake in West Pharmaceutical Services by 731.8% in the 4th quarter. William Blair Investment Management LLC now owns 640,735 shares of the medical instruments supplier’s stock valued at $209,879,000 after acquiring an additional 563,705 shares during the last quarter. FMR LLC increased its holdings in West Pharmaceutical Services by 83.1% during the 4th quarter. FMR LLC now owns 1,090,603 shares of the medical instruments supplier’s stock valued at $357,238,000 after acquiring an additional 494,828 shares in the last quarter. Finally, Seilern Investment Management Ltd acquired a new position in West Pharmaceutical Services during the fourth quarter worth about $145,379,000. Institutional investors and hedge funds own 93.90% of the company’s stock.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania’s 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania’s 8th Congressional District. He declared candidacy for the 2026 election.

Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.